Oncoclinicas Do Brasil Serviços Medicos

What Oncoclinicas Do Brasil Serviços Medicos does

Oncoclínicas do Brasil Serviços Médicos S.A. is the largest outpatient oncology operator in Brazil, running more than 140 clinics, radiotherapy and chemotherapy centers, genomics laboratories, anatomical pathology labs, and integrated cancer treatment facilities across 40 cities, with operational concentration in Southeast Brazil. The company delivers the full spectrum of outpatient cancer care: chemotherapy, radiotherapy, immunotherapy, targeted therapy, cell therapy, bone marrow transplant, oncological surgery, palliative care, pediatric oncology, and a precision medicine stack built around OC Medicina de Precisão that combines AI, genomics, and digital pathology. It also operates supporting platforms including OC Linha de Cuidado (integrated care pathways), OC Navegação (patient navigation), Jornada Molecular (molecular testing pathway), the Onco-PDO diagnostic test, OC Academia for continuing medical education, OC Journal for research publications, and a Pesquisa Clínica clinical research program.

The business model is a B2B2C healthcare services model: end customers are individual cancer patients, but revenue is collected from private health insurers (convênios) and the Brazilian public health system (SUS) under insurance reimbursement contracts, with patient acquisition driven by direct clinic presence, physician referrals, the patient portal, and a telemedicine/mobile app channel. FY2025 gross revenue was R$6.3 billion (approximately US$1.1–1.2 billion), with Q4 2025 alone reporting US$1.43 billion in revenue but missing forecasts and declining 8.7% sequentially.

The company is currently in severe financial distress. It filed for creditor protection (recuperação judicial) on April 13, 2026 after liquidity fell to roughly 15 days. Drivers include the termination of the Unimed FERJ contract (which had contributed R$864.9 million in receivables and R$800 million in unpaid claims), R$430 million in losses tied to the liquidation of Banco Master, a 600 basis point compression in adjusted EBITDA margin from 20.5% in 2024 to 14.5% in 2025, and the departure of CFO Camille Loyo Faria in March 2026 amid contested talks with Porto Seguro SA over a potential R$1 billion investment in a subsidiary of roughly 200 clinics. Around 70 jobs have been cut and approximately 3,000 patients have experienced treatment delays of about a week.

Name

Oncoclinicas Do Brasil Serviços Medicos

Legal name

ONCOCLINICAS DO BRASIL SERV MEDICOS SA

Website

https://oncoclinicas.com.br

Company type

Public

Founded year

2026

Operating status

Operating

Headcount range

51–100 employees

Short description

Oncoclínicas do Brasil is the largest outpatient oncology network in Brazil, operating 140+ clinics, genomics labs, and integrated cancer treatment centers across 40 cities. It delivers chemotherapy, radiotherapy, genomic diagnostics, and AI-enabled precision medicine to cancer patients through private insurance and the SUS public health system.

Ownership category

akta.pro rank

Product category

Outpatient Oncology Services

NAICS

Offices of Physicians (62111), Other Ambulatory Health Care Services (6219), Medical and Diagnostic Laboratories (6215)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Hospitals (8060), Services-Medical Laboratories (8071)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Oncology & Cancer Specialty Hospitals (HLAFAHAC), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Oncology Telemedicine Platforms (HLALAGAH)

Keywords

• Outpatient oncology services
• Precision medicine oncology
• Cancer treatment network
• Radiotherapy chemotherapy services
• Clinical research oncology

Headquarters

HQ city

Belo Horizonte

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Gross Revenue (Healthcare Services): Oncoclinicas generates gross revenue primarily from providing oncology healthcare services including consultations, chemotherapy, radiotherapy, surgery, immunotherapy, targeted therapy, stem cell transplants, palliative care, diagnostic testing (genomics, pathology, imaging), and integrated cancer treatment across its network of 140+ units. Revenue is derived from private health insurance (convênios) and public health system (SUS) reimbursement. Full-year 2025 gross revenue was R$6.3 billion.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Oncoclinicas do Brasil Serviços Médicos operates one of Brazil's largest outpatient oncology networks, with more than 140 clinics, genomics labs, anatomical pathology labs, and integrated cancer treatment centers across 40 cities. The company provides comprehensive cancer care including chemotherapy, radiotherapy, immunotherapy, targeted therapy, cell therapy, bone marrow transplant, palliative care, and pediatric oncology, supported by an AI- and genomics-enabled precision medicine platform (OC Medicina de Precisão) and a clinical research program.

Product overview

Oncoclínicas is a Brazilian cancer treatment operator offering a comprehensive oncology platform with over 140 units across 40 cities. The core offering centers on OC Medicina de Precisão, a precision medicine platform that integrates AI, genomics, and digital pathology. The portfolio includes diverse cancer treatments (chemotherapy, radiotherapy, immunotherapy, targeted therapy, cell therapy, bone marrow transplant), diagnostic services (genetic testing, molecular diagnostics, pathological analysis), and support services (patient navigation, palliative care, telemedicine). The company also operates OC Academia for medical education and OC Journal for research publications, supported by a network of clinics, genomics laboratories, and integrated cancer treatment centers.

Differentiator

Problem solved

Functional benefit

Brands

• OC Medicina de Precisão: Precision medicine division using AI, genomics and digital pathology for cancer treatment

Products and services

• OC Medicina de Precisão (OC Precision Medicine) Precision medicine platform that integrates artificial intelligence, genomics, and digital pathology to support oncologists in diagnosis, treatment planning, and patient monitoring across the clinic network, including molecular diagnostics and personalized treatment planning.
• Quimioterapia (Chemotherapy) Chemotherapy treatment services for cancer patients delivered across the outpatient clinic network.
• Radioterapia (Radiotherapy) Radiotherapy treatment services for cancer patients delivered across the clinic network.
• Imunoterapia (Immunotherapy) Immunotherapy treatment services for cancer patients, including infusion center capabilities.
• Terapia-alvo (Targeted Therapy) Targeted therapy treatment services for cancer patients.
• Terapia Celular (Cell Therapy) Cell therapy treatment services for cancer patients, part of the company's advanced therapy portfolio.
• Transplante de Medula Óssea (Bone Marrow Transplant) Bone marrow transplant services for cancer patients delivered within the network.
• Cuidados Paliativos (Palliative Care) Palliative care services for cancer patients to manage symptoms and improve quality of life.
• Oncopediatria (Pediatric Oncology) Specialized pediatric oncology services for children with cancer, delivered within the broader network.
• Teste Onco-PDO Personalized diagnostic test for optimizing cancer treatment selection for individual patients.
• Jornada Molecular (Molecular Journey) Integrated genomic testing and analysis pathway for personalized cancer treatment, including genetic tests, Onco-PDO test, and pathological analysis.
• Análise Patológica (Pathological Analysis) Anatomical pathology laboratory analysis services supporting cancer diagnosis and treatment decisions.
• Testes Genéticos (Genetic Tests) Genetic testing services supporting personalized cancer care and hereditary cancer risk assessment.
• OC Linha de Cuidado (Care Line) Integrated care-line service coordinating the full cancer care pathway - chemotherapy, radiotherapy, surgery, immunotherapy, targeted therapy, stem cell transplant, palliative care, and support services - across the network.
• OC Navegação (Patient Navigation) Patient navigation support service that guides patients through their cancer treatment journey across the network.
• Telemedicina (Telemedicine) Telemedicine services enabling remote oncology consultations and follow-up visits with network oncologists.
• Pesquisa Clínica (Clinical Research) Clinical research services supporting cancer treatment studies and trials, providing patient access to investigational therapies.
• DeLife Support service for cancer patients during treatment, focused on quality-of-life and well-being.

Quantifiable outcome

• R$6.3 billion gross revenue for full year 2025
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

One partnership is on record.

• Unimed FERJminorGTM or Marketing Partner · 1 January 2025Unimed FERJ was a health insurance partner whose non-performing contract was terminated in 2025. The contract had contributed R$864.9 million in receivables and was a source of financial strain for the company. The deliberate termination of this contract was part of Oncoclinicas' strategic shift away from non-performing commercial arrangements.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• US Oncology Network (McKesson): US Oncology Network is one of the largest outpatient oncology practice networks in the US, offering chemotherapy, radiation, precision medicine, and clinical research. Directly comparable to Oncoclínicas' multi-site outpatient cancer-care platform model.
• A.C. Camargo Cancer Center: A.C. Camargo is one of Brazil's largest dedicated oncology hospitals, offering multi-specialty cancer care, diagnostics, and research. Comparable to Oncoclínicas in comprehensive outpatient and inpatient oncology service delivery within Brazil.
• OneOncology: OneOncology is a US-based platform of independent community oncology practices with shared technology, genomics, and clinical research. Comparable to Oncoclínicas' network model integrating precision medicine and research across outpatient clinics.

Broad incumbents

• DASA (Diagnósticos da América): DASA is Brazil's leading diagnostic and pathology laboratory network with genomic and molecular testing capabilities. Comparable to OC Medicina de Precisão's genomic and digital pathology offerings and to Oncoclínicas' anatomical pathology laboratories.
• Hospital Sírio-Libanês: Sírio-Libanês runs a well-known oncology center of excellence in São Paulo, providing chemotherapy, radiotherapy, genomic testing, and clinical trials. Comparable as a premium Brazilian provider of integrated cancer care and precision diagnostics.
• Fleury Medicina e Saúde: Fleury is a major Brazilian diagnostic medicine provider with strong oncology, genomic and pathology testing capabilities. Comparable to the laboratory and diagnostic arm of the Oncoclínicas network.
• Rede D'Or São Luiz: Rede D'Or is Brazil's largest hospital network with growing oncology service lines across multiple states. Comparable in geographic scale and multi-specialty oncology delivery to Oncoclínicas' 140+ outpatient clinic footprint.
• Grupo Oncoclínicas (parent/affiliated entity): Grupo Oncoclínicas (formerly parent brand of the Oncoclínicas&Co platform) is the broader holding entity and brand under which Oncoclínicas do Brasil operates; comparison is warranted because the same executive structure, technology platforms (OC Medicina de Precisão), and clinical programs span both entities.
• Hospital Israelita Albert Einstein: Einstein operates a large oncology program within a broader premium hospital network in São Paulo. Comparable to Oncoclínicas on the precision medicine, clinical research, and high-acuity outpatient oncology dimensions, though anchored in a general hospital system.

Emerging players

• GenesisCare: GenesisCare is a global outpatient oncology and radiotherapy specialist operating integrated cancer centers. Comparable to Oncoclínicas in the outpatient oncology service model, integrated radiotherapy centers, and precision medicine positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtiktok.com/@oncoclinicas
• YouTubeyoutube.com/channel/UCTLjB1xqQs88RiW1JsQHDpQ
• Facebookfacebook.com/GrupoOncoclinicas?fref=ts
• LinkedInlinkedin.com/company/rede-oncocl%C3%ADnicas-do-brasil?trk=cws-btn-overview-0-0
• Instagraminstagram.com/grupooncoclinicas

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncoclinicas Do Brasil Serviços Medicos